{"id":"msdc-0602k","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets the mitochondrial pyruvate carrier complex, enhancing pyruvate transport into mitochondria and improving cellular energy metabolism. This mechanism increases insulin sensitivity and reduces hepatic glucose production, making it potentially beneficial for metabolic disorders including type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).","oneSentence":"MSDC-0602K is a thiazolidinedione-class insulin sensitizer that activates mitochondrial pyruvate carrier (MPC) to improve insulin sensitivity and glucose metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:17.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)"}]},"trialDetails":[{"nctId":"NCT03970031","phase":"PHASE3","title":"A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH","status":"UNKNOWN","sponsor":"Cirius Therapeutics, Inc.","startDate":"2022-06","conditions":"Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis","enrollment":1800},{"nctId":"NCT02784444","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH","status":"COMPLETED","sponsor":"Cirius Therapeutics, Inc.","startDate":"2016-09-14","conditions":"Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis","enrollment":392}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MSDC-0602K","genericName":"MSDC-0602K","companyName":"Cirius Therapeutics, Inc.","companyId":"cirius-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MSDC-0602K is being studied in clinical trials for conditions including Non-alcoholic Steatohepatitis and Type 2 Diabetes. MSDC-0602K is an insulin sensitizer designed to retain the effect of thiazolidinediones on mitochondrial pyruvate carriers with limited PPAR-gamma binding.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}